Recombinant Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [MJFR-14-6-4-2] to Alpha-synuclein aggregate - Conformation-Specific
- Suitable for: ICC/IF, Dot blot, IHC-P
- Reacts with: Human
Overview
-
Product name
Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific
See all Alpha-synuclein aggregate primary antibodies -
Description
Rabbit monoclonal [MJFR-14-6-4-2] to Alpha-synuclein aggregate - Conformation-Specific -
Host species
Rabbit -
Tested applications
Suitable for: ICC/IF, Dot blot, IHC-Pmore details
Unsuitable for: WB -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat
-
Immunogen
Recombinant full length protein within Human Alpha-synuclein aggregate aa 1 to the C-terminus. The exact sequence is proprietary.
Database link: P37840 -
Positive control
- Dot Blot: Recombinant alpha-synuclein filament untreated and treated with 70% formic acid; Recombinant alpha-synuclein monomer; ICC/IF: ReNcell VM differentiated in media containing cAMP and GDNF (without bFGF or EGF) and transduced with Ad5C01 viral vector encoding human alpha-synuclein filament. IHC-P: Mouse colon tissue.
-
General notes
ab209538 is not suitable for WB or other denaturing conditions, as it is conformation-specific.
This antibody is useful for studying Parkinson’s disease and other synucleinopathies including dementia with Lewy bodies and multiple system atrophy.
This antibody was developed with support from The Michael J. Fox Foundation.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
MJFR-14-6-4-2 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - BSA and Azide free (ab214033)
- Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (Alexa Fluor® 488) (ab216124)
- Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (Alexa Fluor® 647) (ab216309)
- Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (Biotin) (ab227047)
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab209538 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | 1/5000. | |
| Dot blot | Use a concentration of 0.0022 µg/ml. | |
| IHC-P | Use at an assay dependent concentration. |
Target
-
Function
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. -
Tissue specificity
Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. -
Involvement in disease
Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Parkinson disease 1
Parkinson disease 4
Dementia Lewy body -
Sequence similarities
Belongs to the synuclein family. -
Domain
The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments. -
Post-translational
modificationsPhosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure. -
Cellular localization
Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons. - Information by UniProt
-
Database links
- Entrez Gene: 6622 Human
- Entrez Gene: 20617 Mouse
- Entrez Gene: 29219 Rat
- Omim: 163890 Human
- SwissProt: P37840 Human
- SwissProt: O55042 Mouse
- SwissProt: P37377 Rat
- Unigene: 21374 Human
see all -
Alternative names
- Alpha-synuclein antibody
- NACP antibody
- Non-A beta component of AD amyloid antibody
see all
Images
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-260603-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)This image is courtesy of an Abreview by Carl Hobbs.ab209538 staining Alpha-synuclein aggregate in rat dorsal root ganglian (DRG) tissue sections by Immunohistochemistry (PFA perfusion fixed frozen sections). Tissue samples were fixed by perfusion with formaldehyde, cut into 20 micron slices and blocked with 2% BSA for 10 minutes at 21°C and antigen retrieval was by heat mediation in citrate buffer. The sample was incubated with primary antibody (1/2000 in TBS/BSA/azide) at 21°C for 2 hours. An Alexa Fluor® 555-conjugated Goat anti-rabbit polyclonal (1/300) was used as the secondary antibody.
-
![Immunocytochemistry/ Immunofluorescence - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-256951-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.2% Triton X-100 permeabilized ReNcell VM (Human neural progenitor) cells labeling Alpha-synuclein aggregate with ab209538 at 1/5000 dilution, followed by Alexa Fluor® 647 Donkey anti-Rabbit IgG (H+L) secondary antibody at 1/400 dilution (red).
Upper panel counterstain: Anti-aggregated alpha-synuclein antibody clone 5G4 at 1/400 dilution, followed by AlexaFluor®488 secondary detection (green).
Lower panel counterstain: Anti-alpha/beta-synculein antibody at 1/200 dilution, followed by Alexa Fluor® 488 secondary detection (green).
Blocking buffer: 3% bovine serum albumin and 2% fetal bovine serum.
ReNcell VM cells were differentiated in media containing cAMP and GDNF (without bFGF or EGF) and transduced with Ad5C01 viral vector encoding human WT alpha-synuclein filament.
Images were reproduced courtesy of Charles River.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-260516-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)This image is courtesy of an Abreview by Carl Hobbs.ab209538 staining Alpha-synuclein aggregate in mouse colon tissue sections by Immunohistochemistry (PFA perfusion fixed frozen sections). Tissue samples were fixed by perfusion with formaldehyde, cut into 20 micron slices, blocked with 2% BSA for 10 minutes at 21°C and antigen retrieval was by heat mediation in citrate buffer. The sample was incubated with primary antibody (1/2000 in TBS/BSA/azide) at 21°C for 2 hours. A biotin-conjugated goat anti-rabbit polyclonal (1/300) was used as the secondary antibody.
-
![Immunocytochemistry/ Immunofluorescence - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-256952-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.2% Triton X-100 permeabilized ReNcell VM (Human neural progenitor) cells labeling Alpha-synuclein aggregate with ab209538 at 1/5000 dilution, followed by Alexa Fluor® 647 Donkey anti-Rabbit IgG (H+L) secondary antibody at 1/400 dilution (red).
Blocking buffer: 3% bovine serum albumin and 2% fetal bovine serum.
ReNcell VM cells were differentiated in media containing cAMP and GDNF (without bFGF or EGF) and transduced with Ad5C01 viral vector encoding human alpha-synuclein filament (Left image). Right image show control vector cells.
Images were reproduced courtesy of Charles River.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-284579-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)This image is courtesy of an Abreview submitted by Carl HobbsAb209538 staining Alpha-synuclein aggregate in Human DLB brain tissue sections by Immunohistochemistry (Formalin/PFA fixed paraffin embedded sections). Tissue was fixed with paraformaldehyde and blocked with 2% BSA for 10 minutes at 21°C; antigen retrieval was by heat mediation in Citric acid. Samples were incubated with primary antibody (1/10,000 in TBS) for 2 hours at 21°C. A biotin conjugated anti-rabbit IgG Goat polyclonal was used as the secondary antibody at 1/300 dilution.
-
![Dot Blot - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-256954-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-dot-blot.jpg)
Dot Blot - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)Dot blot analysis of alpha-synuclein filament labeled with ab209538 at 2.2 ng/ml.
Lane 1: Recombinant alpha-synuclein filament treated with 70% formic acid.
Lane 2: Recombinant alpha-synuclein filament treated with 70% formic acid.
Lane 3: Untreated recombinant alpha-synuclein filament.
Lane 4: Untreated recombinant alpha-synuclein filament.
Alpha Synuclein filaments were generated using full length recombinant alpha-synuclein (aa1-140) by incubation in 20mM TRIS, pH 7.2 at 37 °C with agitation.
Denaturation of filaments with 70% formic acid reduces antibody recognition by 30-100 fold, demonstrating conformation specificity.
Data is provided by Professor Poul Henning Jensen, Aarhus University, Denmark.
-
![Dot Blot - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)](https://www.abcam.com/ps/products/209/ab209538/Images/ab209538-319141-anti-alpha-synuclein-filament-antibody-mjfr-14-6-4-2-conformation-specific-dot-blot.jpg)
Dot Blot - Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)Data is provided by Professor Poul Henning Jensen, Aarhus University, Denmark.Dot Blot showing the reactivity of ab209538 (2 ng/ml) with
F: alpha synuclein Filament
F+FA: alpha synuclein Filament treated in 50% formic acid for 1 h 37oC prior to application to the dot blot.
M+FA: alpha synuclein Monomer treated in 50% formic acid for 1 h 37oC prior to application to the dot blot.
Loading control antibody (1:1000) reacts with Alpha-synuclein irrespectively of it being in a filament, oligomer or a monomer.
Protocols
References (16)
ab209538 has been referenced in 16 publications.
- Olsen LK et al. Viral mimetic priming enhances a-synuclein-induced degeneration: Implications for Parkinson's disease. Brain Behav Immun N/A:N/A (2019). PubMed: 31029796
- Matsui H et al. Age- and a-Synuclein-Dependent Degeneration of Dopamine and Noradrenaline Neurons in the Annual Killifish Nothobranchius furzeri. Cell Rep 26:1727-1733.e6 (2019). PubMed: 30759385
- Han C et al. Exosomes from patients with Parkinson's disease are pathological in mice. J Mol Med (Berl) 97:1329-1344 (2019). PubMed: 31302715
- Ham S et al. Cell-Based Screen Using Amyloid Mimic ß23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of a-Synuclein and Huntingtin Aggregates. Mol Cells 42:480-494 (2019). PubMed: 31250621
- Van Den Berge N et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol 138:535-550 (2019). PubMed: 31254094
